Traditional Chinese Medicine × Modern Scientific Rigor — Discovery-Engine Lens¶
Status: scope-page (2026-05-05). Fourth peer-track exploration vector under the broader gout-solving mission, sister to engineered-lbp-chassis.md (commercial-pharma chassis) and sirna-urat1-modality.md (discovery-engine output, non-microbial). This page formalizes a methodology lens, not a single chassis or mechanism — the lens applies across multiple compounds, formulas, and chokepoints.
Why this page exists¶
The wiki already contains compounds with TCM lineage — but it doesn't name the lineage as a first-class organizing principle. Oridonin (oridonin.md) is from Rabdosia rubescens (冬凌草). Berberine (referenced across nlrp3-inflammasome.md, supplements-stack.md) is from Coptis chinensis (黄连). EGCG (egcg.md) is green tea (绿茶). Theaflavins (theaflavins.md) are black-tea oxidation products. Curcumin (multiple pages) is turmeric (姜黄), TCM-Ayurveda crossover. Resveratrol (nlrp3-inhibitor-screen.md, others) is from Polygonum cuspidatum (虎杖, Hu Zhang). All of these are part of TCM materia medica with documented historical use; the wiki treats them as modern bioactive small molecules without naming where the empirical signal originally came from.
This page makes the lineage explicit — and frames it as a discovery-engine output the platform contributes mechanistic clarity to (per open-enzyme-vision.md §2.2 two-output architecture: discovery engine + strain library). Open Enzyme's contribution is the methodology + chokepoint-mapped compound analysis + ChEMBL cross-check + falsification card discipline. Partner companies, supplement formulators, clinical researchers, or open-source recipe contributors take findings forward.
The reframe matters because TCM is the largest empirical dataset in human history. Two-thousand-plus years of observation × millions of patient-trial-equivalents = an enormous prior. Modern mechanistic biology lets us re-derive what was real signal vs. confounded noise. This is not "alternative medicine" — it's mining a vast empirical dataset with modern tools.
The discipline — what "TCM × modern rigor" actually means¶
Six rules. Applied to every TCM compound, formula, or claim that enters the wiki under this lens.
1. Mechanism mapping (chokepoint-grounded)¶
Every TCM compound that enters the wiki must be mapped to a specific chokepoint in the modern map (nlrp3-exploit-map.md, gout-pathophysiology.md) — NLRP3 (CP0 through CP6b), ABCG2 (gut + renal), URAT1, GLUT9, XO (xanthine oxidase), or a named adjacent target. Compounds that can't be mapped get tagged Mechanistic Extrapolation (which is honest — "we don't yet know how this works at the molecular level") rather than dressed up with vague "anti-inflammatory" claims.
2. ChEMBL cross-check (curated bioactivity, not folk claim)¶
Every claimed mechanism gets cross-checked against ChEMBL's curated bioactivity data per etc/chembl-cross-check.md. This is the discipline that already produced the Open Enzyme corpus's most useful surprises:
- Berberine's most-potent ChEMBL bioactivity is TDO (tryptophan 2,3-dioxygenase) at 30 nM, not NLRP3. Berberine's NLRP3-pathway claim is via NF-κB / TLR4 modulation — real, but indirect.
- Resveratrol's most-potent ChEMBL bioactivity is DPP-4 at 0.6 nM, not SIRT1. The SIRT1 / NF-κB story rests on mechanism rather than potency.
- EGCG's most-potent ChEMBL bioactivity is 20S proteasome at 86 nM — upstream of NF-κB, but functionally relevant to NLRP3 priming.
Each cross-check tightens the mechanism story and surfaces non-obvious off-targets that classical TCM didn't have language for. The bar: if a claimed mechanism has no curated ChEMBL bioactivity at biologically achievable concentrations, the claim is Mechanistic Extrapolation, not Supported.
3. Bioavailability honesty — embrace gut-luminal mechanisms¶
TCM compounds frequently have terrible oral systemic bioavailability. Curcumin <1%, resveratrol heavily first-pass-metabolized, baicalein gut-conjugated, oridonin moderate but variable. Classical Western pharmacology dismissed this as "the compounds don't work systemically." That framing is wrong for at least some TCM compounds.
Most orally-administered TCM compounds achieve high gut-lumen concentrations precisely because they don't get absorbed. This fits Open Enzyme's gut-lumen sink thesis (gut-lumen-sink.md) perfectly. A TCM compound that:
- Reaches the colon at high concentration (because systemic absorption is poor),
- Modulates ABCG2 expression locally (e.g., curcumin per
abcg2-modulators.md§"The supplements-stack contradiction"), - Or modulates the gut microbiome (berberine's documented Bacteroidetes / Firmicutes shift),
- Or interacts with gut-resident immune cells (sulforaphane, EGCG locally)
— is acting via mechanisms that classical bioavailability metrics miss. The bar: bioavailability is reported honestly (with the gut-vs-systemic split named) and the gut-luminal mechanism is treated as legitimate, not as a fallback explanation.
This is the same discipline as comp-004 (supplement-abcg2-antagonism-computational.md) which explicitly modeled curcumin's gut-luminal concentration via the dose-bioavailability paradox.
4. Formula decomposition (designed coverage vs. redundancy)¶
Classical TCM uses multi-herb decoctions — typically 5-15 components per formula for chronic conditions. The classical Si Miao San (四妙散) for gout / damp-heat Bi syndrome is a four-herb formula. The classical Bai Hu Jia Gui Zhi Tang has eight-plus components. Modern reductionism wants to extract the "active ingredient." But TCM formulators were doing chokepoint coverage by design — different herbs hitting complementary mechanisms.
The bar: when a TCM formula enters the wiki, decompose it. Map each component to its chokepoint(s). Identify whether the formula's design is:
- Designed coverage — components hit different chokepoints (truly multi-mechanism therapy)
- Redundant — components hit the same chokepoint (one is doing the work; others are tradition or buffer)
- Synergistic in a specific way — one component improves the bioavailability or efficacy of another (verifiable mechanistically)
This decomposition is exactly the same analytical structure as koji-endgame-strain.md §1 coverage matrix — naming which chokepoints each payload hits.
5. Standardization (defined extracts, not raw herb)¶
Wild-collected TCM herbs vary 10–100× in active-compound content depending on growing region, season, age, drying method, storage. Modern rigor requires defined extracts with documented active-compound concentrations. The bar: any TCM-derived intervention proposed to the wiki specifies the standardized extract (e.g., Theracurmin, NovaSOL micellar curcumin, oridonin from a defined Rabdosia extract) or notes "standardization is unresolved" as an open question.
5a. TCM Extract Characterization SOPs — tiered framework (added 2026-05-08)¶
Rule #5 above sets the bar; this subsection fills the operational gap by adapting the four-tier framework from medicinal-mushroom-extract-sops.md SOP-6 (which itself adapts enzyme-quantification-protocol.md) to TCM compound classes. The pattern is the same: kitchen → smartphone colorimetry → bench HPLC → outsourced GMP-grade, with the calibrate-once-at-Tier-3, track-batches-at-Tier-½ discipline that makes home-feasibility tractable for any open-source contributor.
Tier table — comp-013 priority compounds:
| Compound | TCM source | Tier 1 (kitchen, ~$0) | Tier 2 (smartphone colorimetry, ~$50) | Tier 3 (bench HPLC, ~$2K) | Tier 4 (outsourced GMP) |
|---|---|---|---|---|---|
| Luteolin | Lonicera japonica (金银花), Achyranthes bidentata (牛膝); also dietary (parsley, celery, peppers) | Visual + dosing-by-known-extract-ratio against a Tier 3 calibrated batch | AlCl₃ colorimetric flavonoid assay (~415 nm yellow). Well-established for total flavonoids; caveat: NON-SELECTIVE — quantifies total flavonoids, not luteolin specifically. Useful as batch-to-batch consistency check ("this batch is in the same flavonoid ballpark as the calibrated reference"); not as luteolin-specific quantification. Rutin equivalents the standard expression. | HPLC-DAD with luteolin reference standard (Sigma L9283). Calibration curve at 350 nm. The load-bearing Tier-3 assay. | Outsourced GMP-grade HPLC if regulatory submission ever needed |
| Astilbin | Smilax glabra (土茯苓) — the canonical PO-HUA-model gout indication compound per comp-013 | Visual + dosing-by-known-extract-ratio | AlCl₃ colorimetric (astilbin is a flavanonol — same chemistry; same caveat) OR Folin-Ciocalteu total phenolics (~765 nm); both are non-selective for astilbin specifically. Use as consistency check, not quantification. | HPLC-DAD with astilbin reference standard (Sigma SMB00478 or equivalent); 290 nm detection. The load-bearing assay for the comp-013 astilbin claim. | Outsourced GMP-grade |
| Emodin | Rheum officinale (大黄), Polygonum cuspidatum (虎杖) | Visual + extract-ratio | Bornträger reaction (emodin is an anthraquinone — alkaline solution turns red, ~520 nm). Smartphone-readable, well-established. Caveat: total anthraquinones — co-extracted aloe-emodin, chrysophanol, rhein all give signal. | HPLC-DAD with emodin reference standard; 254/450 nm detection (anthraquinones absorb at both UV and visible) | Outsourced GMP-grade |
| Berberine | Coptis chinensis (黄连), Phellodendron chinense (黄柏) | Visual (yellow color of crude extract is itself partially indicative) + dosing-by-known-extract-ratio | Dragendorff reagent colorimetric (orange precipitate with alkaloids, ~470 nm in TLC-densitometry) OR direct UV at 345 nm (berberine has a distinctive UV-Vis spectrum). Caveat — alkaloid total — berberine + palmatine + jatrorrhizine all give Dragendorff signal in Coptis; direct UV at 345 nm is more selective. | HPLC-DAD with berberine reference standard (Sigma B3251); 345 nm detection. | Outsourced GMP-grade |
| Rhein | Rheum officinale (大黄) — same source as emodin | Visual + extract-ratio | Same Bornträger reaction as emodin (rhein is a related anthraquinone). Same total-anthraquinone caveat. | HPLC-DAD with rhein reference standard; 254/430 nm detection | Outsourced GMP-grade |
Operational pattern (the calibrate-once-track-batches discipline):
- Tier 3 once per cultivar / batch source. When a contributor sources a new extract (specific Smilax glabra cultivar, specific Coptis chinensis vendor, etc.), run Tier 3 HPLC against the certified reference standard once. This produces the calibrated mg-compound-per-gram-extract value for that source.
- Tier ½ every batch. Subsequent batches from the same source get Tier 2 colorimetry (or just Tier 1 visual + dosing-by-extract-ratio) compared against the Tier-3-calibrated reference. The Tier 2 number is interpreted as "this batch is X% above/below the calibrated reference" — NOT as an absolute quantification (because the colorimetric assays are non-selective for the specific compound).
- Re-Tier-3 at trigger conditions. New cultivar, new vendor, suspect storage degradation, or any other reason to suspect the source has shifted requires re-running Tier 3 to recalibrate.
Tier ½ non-selectivity is the load-bearing caveat across compound classes. Same pattern as SOP-6's GLPP phenol-sulfuric (total polysaccharide, not GLPP-specific). The Tier 2 assays in the table above are useful for consistency tracking but cannot substitute for Tier 3 HPLC for the actual compound-of-interest quantification. Tier 3 HPLC is non-negotiable as the load-bearing assay, with Tier 4 (outsourced GMP) reserved for regulatory-submission scenarios that aren't yet on the OE Phase 0 roadmap.
Reproducibility target: consistent dose-response shape across operators and source-batches; absolute potency may vary 2× operator-to-operator on cell-based downstream assays (typical for biological readouts), but the consistency check at the extract-characterization layer prevents that variance from compounding with extract-batch variance.
Cross-references: medicinal-mushroom-extract-sops.md SOP-6 (parent framework); enzyme-quantification-protocol.md (original koji-track framework); tcm-gout-compound-triage-computational.md (comp-013 priority compounds + verdicts); synthesis archive 2026-05-07 77d0f6e Connection 2 / Item 21 walkthrough.
6. Falsification card per major claim¶
Per linter-design.md and the existing H01 / H02 / H03 cards, any TCM-derived claim that becomes load-bearing for a platform decision (e.g., "Smilax glabra is a viable koji-payload candidate," or "Si Miao San as adjunct to allopurinol shows additive UA reduction") gets a falsification card with assumption stack + killshot menu + pre-committed thresholds. The bar: TCM-source compounds get the same falsification discipline as engineered enzymes. No epistemic carve-out for "but it's traditional."
H04 stub at hypotheses/H04-tcm-rigor-intersection.md is the meta-card for the lens itself; specific compound or formula claims would get H05+ as they emerge.
7. Query-framing discipline — traditional-name FIRST, mechanism-name SECOND (added 2026-05-19)¶
For non-Western-medicine compound discovery, query by traditional-formula-name + species-name + traditional-pathology-framing IN ADDITION TO mechanism-name. Mechanism-name is the wrong starting point for non-Western literature — it silently filters out the traditional-name-anchored papers that the Western citation network underweights.
The canonical worked example (comp-018 Phase 2, 2026-05-16): what looked like a "language barrier" preventing discovery of Houttuynia cordata's complement-inhibitory activity was actually a query-framing mismatch. Chen Daofeng / Yamada-Kiyohara research groups publish 80–95% in English-language journals — language wasn't the gate. The actual gate: a "C3 convertase inhibitor" query missed Houttuynia, while a "Houttuynia cordata anti-complementary" query catches it directly. The real barriers were citation-network insularity + traditional-name vs mechanism-name query framing + source-journal impact-factor underweighting — three failure modes that all get rolled up into "language barrier" framings but are operationally different.
Why this is its own discipline, not a sub-point of §2 (ChEMBL cross-check): ChEMBL is curated bioactivity data; the query-framing discipline is about what literature you read before consulting ChEMBL. ChEMBL undercoverage (documented in comp-013 TCM gout, comp-014 medicinal mushrooms, comp-018 upstream complement, comp-020 verification re-run) reflects what's been curated; traditional-name-anchored papers that never made it into ChEMBL's curation pipeline are invisible to mechanism-name search regardless of language. The query-framing discipline closes a different gap than ChEMBL cross-check.
Cross-mechanism generalization (Pass 3 confirmed, Cluster M walkthrough):
- URAT1 inhibitors: "URAT1 inhibitor natural product" misses Smilax glabra formulations; "Si Miao San 四妙散 hyperuricemia" catches them.
- XO inhibitors: "XO inhibitor flavonoid" misses many curcuminoids; "Jiang Huang 姜黄 xanthine oxidase" (turmeric) catches them.
- NLRP3 inhibitors: "NLRP3 inhibitor natural product" misses G. lucidum spore-powder evidence; "Lingzhi 灵芝 anti-inflammatory mechanism" catches it.
Operational pattern for lit-scan briefings: include traditional-formula-name + species-name + traditional-pathology-framing query variants when the compound class has non-Western traditional-use literature. The CLAUDE.md global-multilingual rule (§"Global-multilingual research by default" → "Query-framing discipline") now encodes this as a project-wide convention.
Cross-reference: CLAUDE.md §"Global-multilingual research by default" (Query-framing discipline bullet); upstream-complement-modulator-sweep-computational.md Phase 2 (the comp-018 finding that surfaced the discipline).
Candidate compounds with classical gout indication¶
Compounds explicitly named in classical TCM materia medica for gout-like presentations (痛风 tongfeng, 痹证 Bi syndrome with hot/damp character, 高尿酸血症 hyperuricemia in modernized parlance). The "wiki status" column shows what the corpus already covers vs. what's a genuine gap.
| Compound | Source / Pinyin | Classical gout indication | Modern mechanism | Wiki status | Bioavailability (oral) |
|---|---|---|---|---|---|
| Smilax glabra | Tu Fu Ling 土茯苓 | Direct — primary gout herb in TCM materia medica | XO inhibition + uricosuric (URAT1 modulation) | Not in wiki — gap | Low systemic; gut-luminal active |
| Rheum officinale | Da Huang 大黄 (rhubarb) | Damp-heat drainage; gout via XO + anti-inflammatory | Emodin, chrysophanol — XO inhibition + NF-κB | Not in wiki — gap | Variable; emodin gut-modified |
| Plantago asiatica | Che Qian Zi 车前子 | Uricosuric; classical "damp-heat in joints" formula component | Aucubin, polysaccharides — URAT1 modulation in animal models | Not in wiki — gap | Low systemic; gut + renal active |
| Phellodendron amurense | Huang Bai 黄柏 | Heat-clearing, gout-like presentations | Berberine (already in wiki via supplements-stack.md) + obacunone | Berberine partial; Phellodendron-specific gap | Berberine ~5%; Phellodendron mixed |
| Polygonum cuspidatum | Hu Zhang 虎杖 | Damp-heat clearing, gout-adjacent | Resveratrol + emodin (resveratrol in wiki via NLRP3 pages) | Partial (resveratrol covered, plant-source not) | Resveratrol ~1% systemic; gut active |
| Cinnamomum cassia | Rou Gui 肉桂 / Gui Zhi 桂枝 | Component of Bai Hu Jia Gui Zhi Tang gout formula | Cinnamaldehyde — anti-inflammatory; modest XO | Not in wiki | Cinnamaldehyde ~75% — actually high |
| Atractylodes macrocephala | Bai Zhu 白术 | Damp-resolving in gout formulas | Atractylenolides — anti-inflammatory; some XO | Not in wiki | Low systemic |
| Astragalus membranaceus | Huang Qi 黄芪 | Adjunctive in chronic gout formulas | Astragalosides — adaptogenic; modest XO | Not in wiki | Astragaloside IV ~3% |
Plus the compounds the wiki already covers that have explicit TCM lineage (and would benefit from explicit lineage-naming in their pages):
| Compound | TCM source / lineage | Existing wiki page |
|---|---|---|
| Oridonin | Rabdosia rubescens (Dong Ling Cao 冬凌草) — TCM "heat-clearing detoxification" | oridonin.md |
| Berberine | Coptis chinensis (Huang Lian 黄连) — TCM "damp-heat" | mentioned in supplements-stack.md, nlrp3-inflammasome.md |
| EGCG | Green tea (Lu Cha 绿茶) — TCM long-history medicinal use | egcg.md |
| Theaflavins | Black tea (Hong Cha 红茶) — TCM-adjacent | theaflavins.md |
| Curcumin | Turmeric (Jiang Huang 姜黄) — TCM + Ayurveda crossover | mentioned in nlrp3-inflammasome.md, abcg2-modulators.md, comp-004 |
| Resveratrol | Polygonum cuspidatum (Hu Zhang 虎杖) — TCM source antedates wine context | mentioned in nlrp3-inflammasome.md |
Classical formulas worth modern re-evaluation¶
A short list, ordered by gout-specific evidence strength:
- Si Miao San / Si Miao Wan (四妙散 / 四妙丸) — four-herb formula explicitly used in TCM for damp-heat Bi syndrome with hyperuricemic presentations. Components: Phellodendron (Huang Bai), Atractylodes (Cang Zhu), Achyranthes bidentata (Niu Xi), Coix lacryma-jobi (Yi Yi Ren). Modern Chinese RCTs (multiple ChiCTR-registered) report 0.5-1.5 mg/dL UA reduction; some show additive effect with allopurinol. This is the highest-priority single formula for modern re-evaluation.
- Bai Hu Jia Gui Zhi Tang (白虎加桂枝汤) — classical "white tiger plus cinnamon twig" formula for gout flares with febrile component. Eight-plus components; complex. Several Chinese clinical trials.
- Modified Si Miao formulas — many regional / school variations with added Smilax glabra (Tu Fu Ling) for stronger uricosuric effect. The Smilax-enhanced versions have specific clinical data.
The Phase 2 lit scan (P2-1 below) would systematically evaluate the Chinese clinical trial registry (ChiCTR) for these formulas + extract the modern Chinese-language evidence base.
Why this fits Open Enzyme structurally¶
Three reasons this is not just a side interest:
-
The chokepoint methodology natively suits multi-compound formulas.
modality-chokepoint-matrix.mdalready maps modalities × chokepoints. TCM formulas are exactly that: multiple compounds covering different chokepoints by design. The framework already exists. -
Gut-luminal mechanism is a perfect fit. Many TCM compounds have low systemic bioavailability — usually treated as a limitation. For Open Enzyme's gut-lumen sink thesis, that's a feature. A TCM compound that stays in the gut and modulates ABCG2 / NLRP3 / microbiome locally is exactly the right pharmacology for the platform's primary mechanism.
-
It's a discovery-engine output, not a strain-library output. Same positioning as
sirna-urat1-modality.md— Open Enzyme contributes mechanistic clarity, ChEMBL cross-checks, falsification cards, and chokepoint coverage maps. Partner organizations (Chinese pharma, US supplement formulators, clinical research groups, open-source recipe contributors) take findings forward to formulation, manufacturing, and clinical trials. This preserves the clean two-track narrative — strain library AND discovery engine.
Comparison with sister peer tracks¶
| Dimension | Koji chassis | LBP chassis | siRNA / URAT1 | TCM × rigor (this page) |
|---|---|---|---|---|
| OE output type | Strain library | Strain library (commercial-pharma sub-track) | Discovery-engine output | Discovery-engine output |
| Manufacturing path | Home-fermentable | Anaerobic bioreactor | Synthetic oligonucleotide | Standardized herbal extract OR synthesized compound |
| Regulatory path | GRAS food / DSHEA supplement | FDA LBP biologic | FDA biologic (BLA) | DSHEA supplement, food, OR Chinese pharma path |
| Distribution | Open-source spores | Pharmacy / mail-order | Subcutaneous injection in clinic | Supplement / functional food / TCM clinic |
| Capital to first commercial dose | $0–500K | $50–200M | $200–500M+ | Variable; $0–10K for self-experiment / supplement, $1–10M for clinical trial |
| Time to first commercial dose | Months | 5–8 years | 10+ years | Months for supplement; 3–7 years for FDA-cleared botanical drug |
| Empirical prior | Modern engineering literature | Modern engineering + LBP clinical | Inclisiran / patisiran precedent | 2,000+ years of TCM observational data (the distinctive feature) |
| Patient population | Broad gout market | Q141K / refractory | Adherence-limited / hepatic-impaired / hormone-modulated | Self-experimenter, supplement-aware, TCM-aware (often overlapping with Brian's profile) |
| OE platform role | Primary chassis | Peer-track scope page + Phase 2 follow-ups | Discovery-engine output; partner / spinout | Discovery-engine output; methodology lens applied across compound corpus |
The four tracks together represent the chase-every-avenue framing: koji for the broad democratized market, LBPs for the durable-colonization / refractory subset, siRNA for the long-horizon mechanistically-cleanest frontier, TCM × rigor for the empirical-prior re-mining vector.
Open Follow-Ups¶
Six in silico Phase 2 follow-ups, no pharma-partner dependency to start. Tracked across the redundant surfaces (this page, open-questions.md, computational-experiments.md, hypotheses/H04-tcm-rigor-intersection.md, index.md, and synthesis/).
| ID | Item | Type | Status |
|---|---|---|---|
| P2-1 | Lit scan: classical TCM gout formulas + modern Chinese clinical evidence (Si Miao San family, Bai Hu Jia Gui Zhi Tang, Smilax-enhanced variations). Global multilingual sources by default — ChiCTR registry (Chinese), CNKI / WanFang (Chinese-language papers, read in original), J-STAGE (Japanese — Japan also has TCM-derived gout literature via Kampo medicine), PubMed (English-translated subset only as cross-check). Output: evidence-tier-tagged summary of which formulas have credible clinical signal vs. which are tradition-only. | Literature review (Opus subagent) | Queued |
| P2-2 | ~~comp-011~~ → comp-013: ChEMBL cross-check + comp-007 composite scoring of 9 candidate TCM gout compounds (renumbered after comp-011 was reassigned 2026-05-05 to C. utilis uricase). COMPLETE 2026-05-06 — see tcm-gout-compound-triage-computational.md. Verdict: 4 GUT-LUMINAL VIABLE (luteolin, astilbin, emodin, berberine) + 1 MODERATE / dose-caveat (rhein) + 4 MECHANISM UNCLEAR (aucubin, cylindrin, chlorogenic acid, atractylenolide I). Most-represented mechanism: URAT1 expression downregulation in murine PO model (5-25 mg/kg active range across 3 of the 4 viable candidates). Key meta-finding: ChEMBL coverage gap is load-bearing — 5 of 9 compounds are not curated at all. The chembl-cross-check discipline (rule #2 of this page) needs amendment: for TCM compounds with sparse ChEMBL coverage, animal-model in vivo dose-response data must be admissible to the verdict. |
Computational analysis (Opus subagent) | ✓ Complete (comp-013) |
| P2-3 | Lit scan: Smilax glabra (Tu Fu Ling) deep-dive. Highest-leverage single-compound — explicit primary gout herb in classical TCM with substantial modern Chinese clinical literature. Modern data on XO inhibition kinetics, uricosuric mechanism, standardization issues, drug interactions, and any documented adverse effects. | Literature review (Opus subagent) | Queued |
| P2-4 | Lit scan: Si Miao San multi-component coverage analysis. Decompose the four-herb formula per "Formula decomposition" discipline above. Map each component to chokepoints. Identify whether the formula's design is designed-coverage / redundant / synergistic. | Literature review + analysis (Opus subagent) | Queued |
| P2-5 | Falsification card H04: TCM × rigor methodology lens. Stub committed at hypotheses/H04-tcm-rigor-intersection.md; full population queued. Includes the meta-claim that the methodology lens itself produces actionable findings vs. is just compound-cataloging. |
Hypothesis formalization | Stub committed; full population queued |
| P2-6 | Bioavailability characterization for the top 3 compounds advancing from P2-2. Quantitative oral bioavailability + gut-vs-systemic distribution + first-pass metabolism + microbiome metabolism. Maps to the "embrace gut-luminal mechanisms" discipline. | Literature review (Opus subagent) | Queued |
| P3 | Platform-framing reflection (rolled into the existing Strategic Reflections Queue entry in synthesis/ (architecture: synthesis/README.md)): does the TCM-rigor track accumulate enough substance to elevate this from "methodology lens" to "first-class discovery-engine output named in open-enzyme-vision.md §2.2 alongside the repurposing-surface candidates"? Trigger: after P2-1 through P2-6 land. |
Strategic reflection | Queued, content-triggered |
Limitations¶
- Standardization variability. Wild-collected herbs vary 10–100× in active compound content. Modern findings on a defined extract (e.g., a specific Smilax glabra root extract from a specific cultivar) may not generalize to other extracts marketed as "Smilax glabra." This page's discipline rule #5 names this; the Phase 2 work should specify standardized extracts where possible.
- Multi-component complexity. TCM formulas have 4-15 components; reductionism vs. holism is a real epistemic tension. The "formula decomposition" discipline (rule #4) tries to navigate this, but some genuinely synergistic interactions may be miscategorized as "redundant" if the synergy mechanism isn't captured by the chokepoint map.
- The line between rigor and "alternative-medicine-washing." TCM-derived claims have a long history of being dressed up with the language of modern science to sell supplements without underlying rigor. The disciplines above are the guardrails, but the lens itself can fail if applied superficially. Brian's editorial discipline + the falsification card framework are the human-side checks against this failure mode.
- Open Enzyme expertise gap. The platform's center-of-mass is engineered fungal genetics + chokepoint mapping. TCM pharmacology, classical Chinese medical theory, and Chinese clinical-trial methodology are outside the in-house competence. Pursuing this track meaningfully would benefit from collaboration with TCM-modernization research groups (especially Chinese university pharmacology departments) or with Western researchers explicitly working at this intersection (e.g., the Shanghai Institute of Materia Medica TCM-modernization program).
Cross-References¶
modality-chokepoint-matrix.md— the matrix this lens applies acrossetc/chembl-cross-check.md— the ChEMBL discipline (rule #2 of the methodology)gut-lumen-sink.md— the gut-luminal mechanism thesis that fits TCM bioavailability honestly (rule #3)oridonin.md,egcg.md,theaflavins.md,supplements-stack.md,nlrp3-inhibitor-screen.md— existing wiki pages on TCM-lineage compoundsengineered-lbp-chassis.md,sirna-urat1-modality.md— sister peer-track scope pages under chase-every-avenueopen-enzyme-vision.md§2.2 — discovery-engine output / repurposing surfaceopen-questions.md— meta-index where the TCM Phase 2 follow-ups will be trackedcomputational-experiments.md— comp-013 (Phase 2 P2-2 closed 2026-05-06) Analyses tabletcm-gout-compound-triage-computational.md— comp-013 interpretive page (per-compound triage verdicts, methodology adaptation notes, cross-cutting findings)hypotheses/H04-tcm-rigor-intersection.md— falsification card stub for the methodology lenssynthesis/Strategic Reflections Queue — Phase 3 platform-framing reflection rolled in../operations/ward-1995-lab-access.md— sister operationalization of the global-multilingual research default (Open Enzyme/CLAUDE.md§"Global-multilingual research by default"). Both pages independently treat language as a non-barrier and proactively map non-English-world resources as first-class assets: this TCM page targets Chinese / Japanese clinical literature (CNKI / WanFang / J-STAGE / ChiCTR / Kampo medicine literature); the Ward 1995 lab-access page targets Japan / China / Europe academic + industrial fungal-engineering groups. Same methodology, different operational domains (literature ingestion vs. resource acquisition). The Maruyama lab at the University of Tokyo (the primary lead in the Ward lab-access page) is itself a parallel instance — Japan publishes substantial fungal-engineering work in Japanese-language journals that English PubMed indexes thinly; the lab-access strategy treats Japanese-language outreach as default, not workaround.